The Research Pharmacy Core (RP) is essential to the translational work of MSKCC. The Core supports the ability of MSKCC to advance its scientific discoveries from laboratory-based investigations to clinical-based Proof-of-Concept testing. The RP has three principal components: 1) The Pharmaceutical Product Facility (PPF) for drug formulation/stability and compatibility issues; 2) The Clinical Grade Production (CGP) Facility for bulk product purification and vialing; and 3) the Pharmacy Investigational Drug Service (PIDS) which supports the preparation and packaging of Investigational drugs for preclinical and clinical use. The RP staff provide consultation, bulk product analysis and purification, formulation, vialing, labeling, stability/sterility testing, and dispensing. The RP works hand-in-hand with the Investigational Products Core to prepare the Chemistry, Manufacturing, and Control Section for each of MSKCC's IND's. Through the RP, MSKCC can advance internal ideas into early human testing. Owing to the infrastructure of the RP, MSKCC has been able to bring multiple distinct types of pharmacologic agents into early clinical trials. These include traditional small molecules, radiopharmaceuticals, and vaccines. The services provided by the core have supported the research of 24 investigators from 5 Programs and 49 IRB protocols in the last year. Since the last review, the work of the Core has contributed to 25 publications from 5 Programs. For example, the therapeutic antibody 3F8 is purified, manufactured, and vialed exclusively at MSKCC and forms the backbone of the research program in neuroblastoma. It has now been validated as an effective treatment for children with neuroblastoma. The large and complex vaccine program, integrating both carbohydrate and peptide vaccines on complex KLH backbone or in mixtures with novel adjuvants is also dependent on the services of the tripartite RP to support the clinical testing of vaccines against cancers Including serous ovarian cancer, leukemia, mesothelioma, and sarcoma.

Public Health Relevance

The Research Pharmacy provides services and expertise associated with the preparation, analysis and dispersion of investigational drugs. The Core is essential to the translational work at the Center and serves as a key conduit to deliver research discoveries from Center investigators to clinicians for human proof-of-concept testing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-51
Application #
9204771
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
51
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Meyer, Jan-Philip; Tully, Kathryn M; Jackson, James et al. (2018) Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. Bioconjug Chem 29:538-545
McFarland, Daniel C; Shaffer, Kelly; Breitbart, William et al. (2018) C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer. Cancer :
Lacouture, Mario E; Anadkat, Milan; Jatoi, Aminah et al. (2018) Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 17:85-96
Blumenthal, Gideon M; Bunn Jr, Paul A; Chaft, Jamie E et al. (2018) Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 13:1818-1831
Shaffer, Kelly M; Nelson, Christian J; DuHamel, Katherine N (2018) Barriers to participation in a sexual health intervention for men following treatment for rectal and anal cancer. Psychooncology 27:1082-1085
Park, Kay J; Patel, Prusha; Linkov, Irina et al. (2018) Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy. Histopathology 72:766-776
Pianko, Matthew J; Goldberg, Aaron D; Lesokhin, Alexander M (2018) Clinical Development of PD-1 Blockade in Hematologic Malignancies. Cancer J 24:31-35
Navi, Babak B; Marshall, Randolph S; Bobrow, Dylan et al. (2018) Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial. JAMA Neurol 75:379-381
Shah, Sona; Boucai, Laura (2018) Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence. J Clin Endocrinol Metab 103:689-697
Goldman, Debra A; Hovinga, Koos; Reiner, Anne S et al. (2018) The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg :1-9

Showing the most recent 10 out of 8799 publications